Literature DB >> 9794599

Does erythropoietin administration affect progression of atherosclerosis in Watanabe heritable hyperlipaemic rabbits?

M Buemi, A Allegra, F Corica, G Calapai, G Cavallaro, C Aloisi, G Pettinato, A Russo, N Frisina.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9794599     DOI： 10.1093/ndt/13.10.2706b

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  4 in total

Review 1.  Role of Erythropoiesis-Stimulating Agents in Cardiovascular Protection in CKD Patients: Reappraisal of Their Impact and Mechanisms.

Authors:  Tetsuji Miura; Tatsuya Sato; Toshiyuki Yano; Akira Takaguri; Takayuki Miki; Noritsugu Tohse; Keitaro Nishizawa
Journal:  Cardiovasc Drugs Ther       Date:  2022-02-12       Impact factor: 3.727

2.  Suppression of coronary atherosclerosis by helix B surface Peptide, a nonerythropoietic, tissue-protective compound derived from erythropoietin.

Authors:  Hiroto Ueba; Masashi Shiomi; Michael Brines; Michael Yamin; Tsutomu Kobayashi; Junya Ako; Shin-Ichi Momomura; Anthony Cerami; Masanobu Kawakami
Journal:  Mol Med       Date:  2013-07-24       Impact factor: 6.354

3.  β Common Receptor Mediates Erythropoietin-Conferred Protection on OxLDL-Induced Lipid Accumulation and Inflammation in Macrophages.

Authors:  Tzong-Shyuan Lee; Kuo-Yun Lu; Yuan-Bin Yu; Hsueh-Te Lee; Feng-Chuan Tsai
Journal:  Mediators Inflamm       Date:  2015-05-25       Impact factor: 4.711

4.  Saphenous Vein Graft Disease Is Associated with a Low Serum Erythropoietin Level.

Authors:  İbrahim Kocaoğlu; Uğur Arslan; Yavuzer Koza; Mustafa Mücahit Balcı; Gizem Çelik; Sinan Aydoğdu
Journal:  Med Princ Pract       Date:  2015-08-14       Impact factor: 1.927
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.